ATE507844T1 - Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates - Google Patents

Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates

Info

Publication number
ATE507844T1
ATE507844T1 AT02736574T AT02736574T ATE507844T1 AT E507844 T1 ATE507844 T1 AT E507844T1 AT 02736574 T AT02736574 T AT 02736574T AT 02736574 T AT02736574 T AT 02736574T AT E507844 T1 ATE507844 T1 AT E507844T1
Authority
AT
Austria
Prior art keywords
molecules
drug
homogeneous
conjugate
cojugate
Prior art date
Application number
AT02736574T
Other languages
English (en)
Inventor
Ward Page Faulk
Original Assignee
Faulk Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulk Pharmaceuticals Inc filed Critical Faulk Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE507844T1 publication Critical patent/ATE507844T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02736574T 2001-05-15 2002-05-15 Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates ATE507844T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29068401P 2001-05-15 2001-05-15
US32953501P 2001-10-17 2001-10-17
PCT/US2002/011891 WO2002091991A2 (en) 2001-05-15 2002-05-15 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use

Publications (1)

Publication Number Publication Date
ATE507844T1 true ATE507844T1 (de) 2011-05-15

Family

ID=26966358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02736574T ATE507844T1 (de) 2001-05-15 2002-05-15 Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates

Country Status (9)

Country Link
US (2) US20040167061A1 (de)
EP (1) EP1414299B1 (de)
JP (1) JP2005514322A (de)
CN (1) CN1307200C (de)
AT (1) ATE507844T1 (de)
CA (1) CA2447391C (de)
DE (1) DE60239938D1 (de)
PL (1) PL373511A1 (de)
WO (1) WO2002091991A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447335C (en) 2001-05-15 2011-01-04 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
EP1404334A4 (de) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Gezielte abgabe von verbindungen mit biologischem einfluss für die krebsbehandlung
CA2447395A1 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
US20040220086A1 (en) * 2001-10-17 2004-11-04 Faulk W. Page Methods and materials for targeting and affecting selected cells
US9333189B2 (en) * 2010-02-03 2016-05-10 Oncbiomune, Inc. Taxane- and taxoid-protein compositions
JP5378469B2 (ja) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
KR20140048404A (ko) * 2012-10-11 2014-04-24 포항공과대학교 산학협력단 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물
EP4637829A1 (de) * 2022-12-20 2025-10-29 Cellis Sp. z o.o. ([Ltd.] Isoliertes gezieltes abgabesystem zur behandlung von ovarialkarzinom

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28686A (en) * 1860-06-12 Improvement in steam-radiators
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
JPH0720886B2 (ja) * 1983-08-10 1995-03-08 ペ−ジ フオ−ク，ウオ−ド タンパク質と抗腫瘍剤との複合体
GB8519457D0 (en) 1985-08-02 1985-09-11 Faulk Ward Page Tumour imaging agents
US5264373A (en) * 1987-02-17 1993-11-23 Abbott Laboratories Fluorescence polarization immunoassay for tetrahydrocannabinoids
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
WO1995003831A1 (en) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates
JPH10502334A (ja) * 1994-04-08 1998-03-03 レセプタゲン・コーポレーション 受容体調節剤およびこれに関連した方法
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6020316A (en) * 1997-09-25 2000-02-01 Lanks; Karl W. Glutaraldehyde modified chemotherapeutic agents and methods of use thereof
JP2002095476A (ja) * 2000-09-20 2002-04-02 Eisai Co Ltd トランスフェリン受容体を介した遺伝子導入法
WO2002076448A1 (en) * 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
EP1404334A4 (de) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Gezielte abgabe von verbindungen mit biologischem einfluss für die krebsbehandlung
CA2447395A1 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
US20040220086A1 (en) * 2001-10-17 2004-11-04 Faulk W. Page Methods and materials for targeting and affecting selected cells

Also Published As

Publication number Publication date
US20090068104A1 (en) 2009-03-12
PL373511A1 (en) 2005-09-05
JP2005514322A (ja) 2005-05-19
CA2447391C (en) 2012-08-28
EP1414299B1 (de) 2011-05-04
US20040167061A1 (en) 2004-08-26
CA2447391A1 (en) 2002-11-21
WO2002091991A2 (en) 2002-11-21
EP1414299A4 (de) 2005-06-22
CN1307200C (zh) 2007-03-28
HK1067492A1 (en) 2005-04-15
DE60239938D1 (de) 2011-06-16
EP1414299A2 (de) 2004-05-06
CN1529551A (zh) 2004-09-15
WO2002091991A3 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
UY27438A1 (es) Composición farmaceútica que comprende un conjugado oligómero-farmaco insulina, método para tratar deficiencia de insulina en un sujeto, método para proveer una composición farmacéutica.
MY137552A (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
ATE472338T1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
MX367615B (es) Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ATE536376T1 (de) Humanes bindungsmolekül gegen cd1a
EP3449946A3 (de) Hydrophobe kernträgerzusammensetzungen zur verabreichung von therapeutika, verfahren zur herstellung und verwendung davon
HRP20050416A2 (en) Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
ATE334676T1 (de) Photo-empfindlichkeit-erhöhende conjugate zur targeting von pathogene
ATE258946T1 (de) Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
HUT76970A (hu) Készítmény az érrendszer specifikus koagulálásához
NO975547L (no) Vaksiner med modifiserte meningokokk/polysakkarid-konjugater
DE60042369D1 (de) Chemisch programmierbare immunität
ATE521366T1 (de) Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
WO2004013307A3 (en) Compounds for targeting hepatocytes
WO2006002895A3 (en) Conjugates of antibody and duoarmycin derivatives as antitumor agents
ATE194776T1 (de) Verfahren zur herstellung von lipid-konjugaten
DE60239938D1 (de) Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
AU2002360350A8 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
DE602005015855D1 (de) Verfahren zur herstellung von immunogenen konjugaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties